about
Genome-wide meta-analyses identify three loci associated with primary biliary cirrhosisRetreatment with interferon plus ribavirin of chronic hepatitis C non-responders to interferon monotherapy: a meta-analysis of individual patient data.Morphological distribution of μ chains and cd15 receptors in colorectal polyp and adenocarcinoma specimensEfficacy and safety of boceprevir plus peginterferon-ribavirin in patients with HCV G1 infection and advanced fibrosis/cirrhosis.Safety and efficacy of boceprevir/peginterferon/ribavirin for HCV G1 compensated cirrhotics: meta-analysis of 5 trials.Incidence and risk factors for non-alcoholic steatohepatitis: prospective study of 5408 women enrolled in Italian tamoxifen chemoprevention trial.Repeated paracentesis and i.v. albumin infusion to treat 'tense' ascites in cirrhotic patients. A safe alternative therapy.High prevalence of multinodular hepatocellular carcinoma in patients with cirrhosis attributable to multiple risk factors.The evaluation of fine-needle procedures for the diagnosis of focal liver lesions in cirrhosis.Clinical expression of insulin resistance in hepatitis C and B virus-related chronic hepatitis: differences and similarities.Is response to antiviral treatment influenced by hepatitis B virus genotype?Recommendations for the management of mixed cryoglobulinemia syndrome in hepatitis C virus-infected patients.Management of HCV patients with cirrhosis with direct acting antivirals.Optimal management of patients with chronic hepatitis C and comorbidities.Current practice of chronic hepatitis B treatment in Southern Italy.Long-term outcome of laparoscopic ablation therapies for unresectable hepatocellular carcinoma: a single European center experience of 426 patients.Effects of acute administration of zetidoline, a new antidopaminergic drug, on plasma prolactin and aldosterone levels in man.Undetectable HCV-RNA at treatment-week 8 results in high-sustained virological response in HCV G1 treatment-experienced patients with advanced liver disease: the International Italian/Spanish Boceprevir/Peginterferon/Ribavirin Name Patients Program.Interferon lambda-3 is not associated with clinical outcome in patients with HCV-induced compensated cirrhosis: a long-term cohort study.The combination of MK-5172, peginterferon, and ribavirin is effective in treatment-naive patients with hepatitis C virus genotype 1 infection without cirrhosis.Overall safety profile of boceprevir plus peginterferon alfa-2b and ribavirin in patients with chronic hepatitis C genotype 1: a combined analysis of 3 phase 2/3 clinical trials.Occult hepatitis B virus infection in patients with non-Hodgkin lymphoma: the need for early diagnosis in anti-Hbc positive patients.Properties of hepatitis B virus pre-S1 deletion mutants.Molecular epidemiology of hepatitis C virus infection among intravenous drug users.Hepatitis C virus genotypes and risk of hepatocellular carcinoma in cirrhosis: a case-control study.Antiviral therapy after complete response to chemotherapy could be efficacious in HCV-positive non-Hodgkin's lymphoma.Refinement of stopping rules during treatment of hepatitis C genotype 1 infection with boceprevir and peginterferon/ribavirin.Hepatitis C virus genotypes and risk of hepatocellular carcinoma in cirrhosis: a prospective study.Hepatitis C virus testing in primary biliary cirrhosis.Quantitative analysis of hepatitis C virus activity in vivo in different groups of untreated patients.Lack of association between circulating HCV-RNA and anti-HCV positivity in primary biliary cirrhosis.Hepatitis C virus genotype 1b as a risk factor for hepatocellular carcinoma development: a meta-analysis.Peginterferon alfa-2b plus ribavirin for naïve patients with genotype 1 chronic hepatitis C: a randomized controlled trial.Clinical significance of hepatic HCV RNA in patients with chronic hepatitis C demonstrating long-term sustained response to interferon-alpha therapy.Dynamics of hypervariable region 1 variation in hepatitis C virus infection and correlation with clinical and virological features of liver disease.Efficacy and safety of peginterferon alfa-2a (40KD) plus ribavirin in hepatitis C patients with advanced fibrosis and cirrhosis.Insulin resistance is associated with steatosis in nondiabetic patients with genotype 1 chronic hepatitis C.Long-term beneficial effects in sustained responders to interferon-alfa therapy for chronic hepatitis C.Sustained virological response to interferon-alpha is associated with improved outcome in HCV-related cirrhosis: a retrospective study.Hepatitis C virus genotype 1b as a major risk factor associated with hepatocellular carcinoma in patients with cirrhosis: a seventeen-year prospective cohort study.
P50
Q28943317-FD9F8EA1-BE02-4564-BB6D-B3FC3E9DB0FDQ30746310-4462412A-08CF-4997-AD49-C7513BDC0E28Q31111890-58C0F522-B7B0-4E22-A970-DE2BA44D553EQ33404560-2BE92176-F814-459B-BE55-F4C209F0281BQ33414720-DDF9152F-21AE-421E-BEE1-FDD5862A6C5EQ33937093-C5126BE5-74E8-4B76-B8C7-9E9FBE7830FCQ34186644-D2B8222F-8636-4AA0-A145-6C6A406CCF1CQ34503653-585D52AD-23F3-45D7-9212-E8C3B54B13BAQ34728068-F3D60C3C-CAF8-481C-9026-EF81DB9CC32BQ37122348-626107AC-161F-4C78-A2E3-8534427FFD18Q37688367-EB2BDD5E-C4B4-40A3-BAEA-24868D4CBEBFQ37838047-5CB46024-CC8D-4596-B52A-2B04DF839323Q38174248-99EDC202-8583-4371-B0FB-A71E9F03E9EAQ38295819-7C25A892-44FE-4788-AC97-BB6083556435Q39494174-5BB8076B-37E2-4941-882C-BEFDEFB2E387Q41481285-0E4A7310-C283-4C26-A703-B703DA22FFCCQ41535823-09985F33-2196-455C-91C3-C80B2E0E3EF4Q41703167-59A6C24D-B8EB-4BAB-8835-CCC9C746324BQ41759513-CE36523F-CEC8-4DF7-85FC-E94DCBFB28D8Q42224935-4F8D46EA-40D8-4F3A-A176-E52FC92B2725Q42263085-03679BA7-A405-4055-B8FD-2BFA21405AB6Q42538067-9AF5A613-FFC1-409A-83C0-6EA7EFEA799FQ42602807-3E0AD054-C775-4A75-995B-D1B9E3681CB8Q42676636-6AB465C9-E839-4F3B-9D4D-17573A0FAF8CQ42977618-5D5A24E3-4891-4A77-9211-249172CE8C81Q42980538-23CD42CA-4BCF-4535-91FB-74F4B4F0E622Q42980599-4D2401E3-E9FF-4C54-97F7-39DA7CE6EC7FQ42981575-DCFE3FC9-0B13-47F2-929D-A94BFE35F0DFQ42981793-BDA70EF8-F389-4A54-B718-B96983617B7AQ42985174-1DB0C21A-E78B-4B4B-9B94-0871C3E46FC7Q42985326-62CD3041-9078-439F-8151-6BA8F3D37B7BQ42987117-78833078-9A24-4B4F-9570-5FE3ADD75A61Q42987199-B29ABE2F-60D5-4310-930F-97EEA15D0A3EQ42987904-DB55407D-8D05-4DE0-ADDF-A25BC47AC0ACQ42988433-8B1BA2D7-A2BE-4F36-8B64-EA97ED4B1CFBQ42992774-CAFBAEAE-205F-453A-927E-3094BCA2BBD6Q42997332-C567C7A1-1C9B-47F2-AB48-811E71432A0CQ43032576-DF3575A6-E970-4FFC-948A-E7D99E0E6842Q43036320-B8E9C994-5D58-4F08-BDB4-1159873B16F3Q43039760-8F7DA997-156E-4BC3-8A21-F12704889D9F
P50
description
hulumtues
@sq
onderzoeker
@nl
researcher
@en
հետազոտող
@hy
name
Savino Bruno
@ast
Savino Bruno
@en
Savino Bruno
@es
Savino Bruno
@nl
Savino Bruno
@sl
type
label
Savino Bruno
@ast
Savino Bruno
@en
Savino Bruno
@es
Savino Bruno
@nl
Savino Bruno
@sl
prefLabel
Savino Bruno
@ast
Savino Bruno
@en
Savino Bruno
@es
Savino Bruno
@nl
Savino Bruno
@sl
P106
P1153
7101967957
P21
P31
P496
0000-0002-3887-864X